Top News

FDA Issues Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted

July 18, 2022

FDA has granted an Emergency Use Authorization to Novavax’s COVID-19 vaccine.

First Successful Efficacy Study Against Omicron With COVID-19 Vaccine

June 27, 2022

The Sanofi-GSK vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial with a high-Omicron environment.

Novartis to Invest $250 Million for R&D of Neglected Tropical Diseases

June 24, 2022

Novartis will endorse the Kigali Declaration on neglected tropical diseases and invest $250 million for R&D.

GSK Announces £1 Billion R&D Investment in Fighting Infectious Diseases in Lower-Income Countries

June 24, 2022

GSK will invest £1 billion in furthering R&D in malaria, tuberculosis, and HIV, as well as neglected tropical diseases.

FDA Authorizes COVID-19 Vaccines for Individuals Six Months and Older

June 17, 2022

FDA has issued an Emergency Use Authorization for the Moderna and Pfizer-BioNTech COVID-19 vaccines in children as young as six months old.

EC Approves Lunsumio, Roche’s Bispecific Antibody for Follicular Lymphoma

June 09, 2022

Roche has received approval from the European Commission for Lunsumio (mosunetuzumab), the first CD20xCD3 T-cell engaging bispecific antibody for treating follicular lymphoma.

Bristol Myers Squibb Acquires Turning Point Therapeutics for $4.1 Billion

June 08, 2022

The acquisition grants Bristol Myers Squibb access to the company's oncology pipeline and lead candidate, repotrectinib.

Lilly to Invest $2.1 Billion in New Indiana Manufacturing Facilities

June 08, 2022

Eli Lilly and Company plans to build two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County.

GSK Acquires Affinivax for $2.1 Billion

June 01, 2022

GSK’s acquisition of Affinivax will give the company access to their portfolio of next-generation pneumococcal vaccines.

Pfizer and BioNTech Granted EUA for Booster Dose of COVID-19 Vaccine in Young Children

May 18, 2022

Pfizer and BioNTech’s COVID-19 vaccine has been granted EUA for booster doses in children five through 11 years of age.